Grants for Small businesses - Federal

This funding opportunity supports small businesses that have completed a Phase II SBIR or STTR award in advancing clinical trials and research projects for medical products, particularly those requiring federal regulatory approval, while encouraging partnerships with investors to ensure commercial viability.

This funding opportunity provides financial support to organizations that will help improve diabetes prevention and management for underserved populations by offering expertise, training, and resources to enhance health equity.

This funding opportunity provides financial support to institutions with active Clinical and Translational Science Awards to develop innovative programs that address critical challenges in clinical research and improve the efficiency of translating scientific discoveries into practical applications.

This funding opportunity supports U.S.-based small businesses in developing and manufacturing therapeutic extracellular vesicles for regenerative medicine applications, focusing on tissue and organ repair.

This funding opportunity provides financial support for innovative research projects aimed at understanding the neurological and mental health effects of chronic illnesses linked to infections, such as Long COVID and chronic fatigue syndrome, encouraging studies that explore their underlying mechanisms.

The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) hereby notify Small Business Concerns (SBCs) holding Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants that funds are available for administrative supplements to improve the diversity of the research workforce by recruiting and supporting students, postdoctorates, and eligible investigators from groups that have been shown to be nationally underrepresented in health-related research or in the SBIR and STTR programs. This supplement opportunity is also available to PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project. Administrative supplements must support work within the scope of the original project. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

This funding opportunity supports community hospitals and oncology practices in expanding access to cancer research and clinical trials for diverse populations, focusing on participant recruitment and insights into local care disparities.

The FY24 DMDRP CTRA mechanism supports advanced translational research that will accelerate the movement of promising ideas in DMD research into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. However, applicants should not view translational research as a one-way continuum from bench to bedside. The research plan must involve a reciprocal flow of ideas and information between applied and clinical research. As such, applications must include preliminary and/or published data relevant to DMD to support the proposed research project.This mechanism is intended to support established projects that have moved beyond the realm of basic research and proof of concept studies and have the potential to result in a near-term impact in clinical research or the clinic. Research projects investigating therapies that will be efficacious across the life span, including infants, toddlers, and non-ambulatory individuals, are strongly encouraged. Pilot, proof-of-principle clinical trials, and correlative studies to better inform development of drugs, devices, and other interventions are allowed.Early-Career Partnering PI Option: The FY24 DMDRP encourages applications that include meaningful and productive collaborations between investigators. In an effort to promote enhanced research capacity within the DMD field, the FY24 CTRA includes an option for an Early-Career Partnering Principal Investigator (PI). The Partnering PI Option is structured to accommodate two PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The Early-Career PI will be identified as the Partnering PI. Both PIs should contribute significantly to the development and execution of the proposed research project. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PI, refer to Section II.D.2, Content and Form of the Application Submission.The FY24 DMDRP CTRA offers two funding levels (refer to Section II.D.5 Funding Restrictions). Only one funding level category may be chosen per application, and the choice of application category is at the discretion of the applicant. The following are generalized descriptions of the scope of the research appropriate for each funding level:Funding Level 1: Funding Level 1 is intended to support smaller, less complex preclinical and/or clinical research. Pilot clinical trials are allowed. The proposal/applications direct costs budgeted for the entire period of performance should not exceed $650,000.Funding Level 2: Funding Level 2 is intended to support larger, more complex preclinical and/or clinical research. Pilot clinical trials are allowed. The proposal/applications direct costs budgeted for the entire period of performance should not exceed $1.35M.Additionally, both funding levels will support an Early-Career Partnering PI Option at the same maximum direct costs and periods of performance, respectively.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Both pilot clinical trials and clinical research are permitted under this mechanism.A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.All investigators applying to FY24 DMDRP funding opportunities and conducting clinical research are encouraged to consult the Strategies to Promote Diversity in Muscular Dystrophy Research Participation developed by the MDCC.

This funding opportunity supports researchers exploring innovative strategies to achieve long-lasting HIV remission at the start of antiretroviral therapy, focusing on basic and preclinical studies rather than clinical trials.

This funding opportunity provides financial support for the design and operation of a facility that extracts and refines rare earth elements from unconventional sources, aimed at strengthening domestic supply chains and reducing reliance on foreign materials.

The U.S. Department of State, Bureau of Democracy, Human Rights, and Labor (DRL), in coordination with the Bureau of East Asian and Pacific Affairs (EAP), announces an open competition for organizations interested in submitting applications for a project that will increase sub-national, democratic, and people-to-people ties between Central and Eastern Europe (CEE) and Taiwan. For the purposes of this solicitation, applicable regions include Central and Eastern Europe, the Baltic states, and the Western Balkans.

This funding opportunity supports small businesses in developing innovative informatics tools that enhance the use and accessibility of the human pangenome reference for genomic research and clinical applications.

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to support early-career academic scientists interested in transitioning to entrepreneurship while also supporting the transfer of technology from academic laboratories into small businesses. Both small businesses and universities are drivers of technological innovation in the United States (U.S.), often working together to advance innovative ideas into products that can benefit the U.S. population. While most NIH funding supports basic research in university laboratories, the NIH also supports innovative technology development in U.S. small businesses through its SBIR and STTR programs. As technologies transition from academic discovery to small businesses, two common challenges arise, identifying the right team with the right expertise to take the product into a small business, and funding for early-stage technology development. This NOFO seeks to address both challenges simultaneously by having two equally important goals: entrepreneurial mentoring support, and product development support.

This funding opportunity supports institutions in training clinical scientists focused on cancer research, enabling them to lead or participate in clinical trials as part of their career development.

This grant provides funding for research and development projects aimed at improving the equipment and support systems for U.S. Army soldiers, focusing on enhancing their survivability, mobility, and overall effectiveness in the field.

This funding opportunity supports clinical research aimed at improving burn care for military personnel, focusing on practical applications that enhance treatment in challenging environments.

This funding opportunity provides financial support to state and local governments, educational institutions, nonprofits, and other organizations to implement strategies that promote better nutrition and physical activity, ultimately reducing chronic disease risks in their communities.

The "DoD Bone Marrow Failure, Investigator-Initiated Research Award" is a grant that provides two levels of funding: one for expanding mature research ideas and key discoveries in bone marrow failure, and another for supporting the development of new drugs for bone marrow failure treatment, with the ultimate goal of improving patient care and finding effective treatments and cures.

This funding opportunity supports institutions in developing training programs for predoctoral and postdoctoral researchers focused on advancing knowledge and skills in aging research, aiming to prepare a diverse group of scientists for careers in this critical field.

The purpose of this funding opportunity is to develop artificial intelligence tools and experimental assays to identify new pharmacotherapeutics with lower toxicity and higher efficacy for substance use disorders (SUD) Areas of interest include but are not limited to: 1) Development of AI tools to identify potential target combinations, design new molecules, conduct virtual preclinical studies to predict efficacy and toxicity, and model in vitro and in vivo polypharmacology 2) Development of assays to assess the effects of compounds on multiple targets or functions